Media Release: NHMRC interim advice strengthens the foundation for evidence-based gender affirming care for young people

Media Release: NHMRC interim advice strengthens the foundation for evidence-based gender affirming care for young people

LGBTIQ+ Health Australia logo AusPATH logo  

Joint media statement, AusPATH and LGBTIQ+ Health Australia.

The Australian Professional Association for Trans Health (AusPATH) and LGBTIQ+ Health Australia (LHA) welcomes the National Health and Medical Research Council’s (NHMRC) interim advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18 (The Advice) for public consultation. 

The Advice includes a conditional recommendation that, as part of a shared decision between the young person, their parents or carers, and their clinicians, puberty suppressants can be considered for a young person (aged under 18) who wants that care, when the young person has commenced puberty, has gender incongruence with or without distress and is assessed as suitable for treatment in collaboration with clinicians.

The conditional recommendation is supported by Good Practice Statements that place the wellbeing of young people at the centre of care, emphasising respect, informed consent, privacy, non-discrimination, and access to safe and inclusive healthcare.

Eloise Brook, CEO of AusPATH, said the advice provides a critical update to Australia’s established approach to gender-affirming healthcare for young people.

“The Advice recognises that puberty suppressants can be a treatment option in the care of people aged under 18 with gender incongruence. The use of puberty suppressants is one possible part of care, not the entirety of care, and it is not necessary to wait until a young person is distressed before providing care.”

“The Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents developed by the Royal Children’s Hospital Melbourne, provide an important framework for clinical practice in Australia. The NHMRC’s interim advice is a valuable addition that supports continuing evidence-informed decision-making, clinical governance and high-quality care. It reflects the ongoing evolution of clinical practice and healthcare guidance in gender affirming care, consistent with clinical guideline development processes across all areas of health.”

“As with all NHMRC guidelines, recommendations are informed by the best available evidence currently available and are updated as new evidence emerges. This advice provides an important foundation for continued evidence review, clinical excellence and high-quality care.”

“It is important that the current Standards remain the foundation of care while the NHMRC progresses its work towards comprehensive national guidelines, with the interim advice contributing to and sitting alongside the existing best-practice approaches,” said Brook.

Nicky Bath, CEO of LGBTIQ+ Health Australia, welcomed the advice as an important validation of evidence-based clinical practice in Australia.

“The NHMRC is one of Australia's most respected health and medical institutions, with responsibility for developing evidence-informed guidance across a broad range of health areas. Its processes are recognised for their rigour, independence and commitment to scientific evidence.”  

"The strength of this advice lies in the expertise behind it. The committee brought together clinical experts, researchers and people with lived experience to carefully consider the evidence and its implications for young people and their families. That gives confidence that the advice is both rigorous and reflective of both the evidence and lived experience."

With the final guidelines not expected until mid-2028, AusPATH and LHA are calling on all governments to act now to support nationally consistent access to appropriate healthcare.

Brook said, “The interim advice provides an important opportunity for governments to improve equitable access to care across the country. Governments must invest in the clinical services, workforce development and research needed to ensure high-quality care is available to everyone who needs it.”

Bath said, “We encourage jurisdictions where access to care is more limited to consider the NHMRC's advice as part of ongoing policy and clinical review. Consistency in healthcare delivery is important to ensure young people and families can access appropriate support, irrespective of where they live.

AusPATH and LHA note that the consultation process on the interim is now open and encourages participation.

AusPATH and LHA will host a joint webinar on Wednesday 25 November 2026 from 1:00 to 2:00pm AEDT. Further details will be published on LHA’s website in due course.

– END –

Read the interim advice here: https://www.nhmrc.gov.au/health-advice/guidelines-care-trans-and-gender-diverse-people/advice-puberty-suppressants

 


View Full Media Release (PDF)

MEDIA CONTACT: 

Mylo Norman. Pronouns: He/Him
Communications Manager

Mobile: 0473 141 779 | Email: [email protected]